Furthermore, exenatide treatment for 16 weeks in T2D patients reduced levels of inflammatory markers in the blood, including high-sensitivity CRP and monocyte chemoattractant protein-1 (MCP-1), as well as the level of the oxidative stress marker 8-iso-prostaglandin F2a (PGF2a), in addition to reducing body weight and improving glucose profile and HbA1c levels [123]. Here, CCL2 is linked to type 2 diabetes mellitus.